DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Crompton Greaves, Delhivery among 10 mid-cap stocks analysts expect to rally up to 53%
18/05/2025
Understanding high dividend yield stocks
18/05/2025
F&O Talk : Market mood lifts, Nifty to eye 24,740 as immediate target : Rahul Ghose
18/05/2025
Sebi mandates e-book mechanism for pvt debt securities above Rs 20 cr
18/05/2025
Q4 results this week : ITC, Sun Pharma, IndusInd Bank, IndiGo, BEL among 81 companies set to announce earnings
18/05/2025
IPO Calendar : Belrise Industries lead 4 IPOs that will rev up primary market next week
18/05/2025
